A Systematic Review of Early Postpartum Medroxyprogesterone Receipt and Early Breastfeeding Cessation: Evaluating the Methodological Rigor of the Evidence
Breastfeeding Medicine2011Vol. 7(1), pp. 10–18
Citations Over TimeTop 20% of 2011 papers
Elizabeth Brownell, I. Diana Fernandez, Cynthia R. Howard, Susan G. Fisher, Sharon Ternullo, Ryan Buckley, Ann Dozier
Abstract
Current evidence is methodologically weak and provides an inadequate basis for inference about a possible causal relationship between early postpartum medroxyprogesterone use and poor breastfeeding outcomes. However, given the presence of a strong biological model describing the potential deleterious effect of postpartum medroxyprogesterone use on lactation, further research that improves on current literature is warranted. Meanwhile, we recommend that potential breastfeeding risks associated with early (<6 weeks) postpartum medroxyprogesterone use be disclosed to allow for a fully informed consent and decision-making process.
Related Papers
- → Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study(2022)3 cited
- → Depo-Provera effects on Wistar rat performance in the Y-maze(2013)9 cited
- → 91240488 Bone density in women receiving depot medroxyprogesterone acetate for contraception(1992)9 cited
- New trends in the use of medroxyprogesterone acetate as a chemotherapeutic agent in gynecologic malignancies.(1992)
- [Possible indications for medroxyprogesterone in the management of breast cancer].(1980)